IKT 8-K 2026-11-10

Inhibikase Therapeutics, Inc. (IKT) 8-K dated 2026-11-10 — accession 0001193125-26-455560.

Inhibikase Therapeutics, Inc. (IKT) is a biotechnology company listed on US.

IKT: Inhibikase Therapeutics Announces Third Quarter 2026

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$19.6M. IKT currently screens at market cap $215.2M.

Not investment advice. The IKT SEC hub lists recent forms. The stock page is the research view.